Is blood‐based kallikrein‐8 increased in participants with subjective cognitive decline compared to cognitively healthy controls? Results of the Heinz Nixdorf Recall Study

While there is rising evidence of blood kallikrein‐8 (KLK8) as a new blood‐based biomarker for mild cognitive impairment due to Alzheimer’s disease (AD) and for AD, little is known about the role of blood KLK8 in earlier prodromal stages of disease. Therefore, the aim of the present study was to examine whether blood KLK8 is elevated in participants with subjective cognitive decline (SCD) compared to cognitively unimpaired controls.